Analysts at JP Morgan initiated coverage on Halozyme Therapeutics HALO with a Outperform rating.
The target price for Halozyme Therapeutics is set to $13.
Halozyme Therapeutics shares have gained 10.07% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.
Halozyme Therapeutics' shares fell 2.82% to close at $9.29 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in